Education
About Us
Working with TipRanks
Follow Us
MacroGenics (MGNX)
NASDAQ:MGNX
MGNX Stock Chart & Stats
$1.40
-$0.07(-2.05%)
At close: 4:00 PM EST
$1.40
-$0.07(-2.05%)
Day’s Range― - ―
52-Week Range$0.99 - $3.60
Previous CloseN/A
Volume157.79K
Average Volume (3M)1.14M
Market Cap
$84.13M
Enterprise Value$67.18M
Total Cash (Recent Filing)$146.40M
Total Debt (Recent Filing)$37.01M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Feb 19, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding63,258,533
10 Day Avg. Volume1,542,612
30 Day Avg. Volume1,139,564
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.75
Price to Sales (P/S)1.37
P/FCF Ratio-2.82
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue0.53
Enterprise Value/Gross Profit0.72
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$3.00Price Target Upside114.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Leadership And StrategyThe CEO transition brings a renewed vision of capital efficiency via current and future partnerships.
New Product DevelopmentThe company will continue development of lorigerlimab in gynecological cancers, focusing on areas where checkpoint inhibitors have historically not demonstrated impressive data.
Promising Preclinical DataPreclinical data for MGC026 appear encouraging, demonstrating strong in vivo efficacy against a range of B7-H3+ LuCaP PDX models.
Bears Say
Competitive LandscapeSeveral other competitors are further ahead in clinical development with their B7-H3-targeted ADCs.
Discontinued DevelopmentThe company has decided to discontinue further development based on the interim data, which failed to show an improvement in rPFS over the control arm for the target population.
Pending Clinical Trial ResultsThe fate of lorigerlimab hinges on the Phase II LORIKEET update, where a path forward may be feasible if an 8+ month rPFS is achieved.
MacroGenics News
MGNX FAQ
What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was $0.99 and its highest was $3.60 in the past 12 months.
What is MacroGenics’s market cap?
MacroGenics’s market cap is $84.13M.
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Feb 19, 2026 which is in 69 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on Nov 12, 2025. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of -$0.446 by $0.716.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -0.2.
How many shares outstanding does MacroGenics have?
MacroGenics has 63,258,533 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of $0.27 in its last earnings report, beating expectations of -$0.446. Following the earnings report the stock price went up 8.844%.
Which hedge fund is a major shareholder of MacroGenics?
Currently, no hedge funds are holding shares in MGNX
MacroGenics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (114.29% Upside)
$3.00 (114.29% Upside)
Blogger Sentiment
Bullish
MGNX Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 188.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.05%
12-Months-Change
Fundamentals
Return on Equity
-81.13%
Trailing 12-Months
Asset Growth
2.37%
Trailing 12-Months
Company Description
MacroGenics
MacroGenics, Inc. is a biotechnology company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company specializes in leveraging its proprietary technologies, such as the DART® platform, to create bispecific antibodies that can engage multiple targets simultaneously, enhancing therapeutic efficacy and safety. MacroGenics operates primarily in the oncology sector, with a portfolio of product candidates aimed at addressing unmet medical needs in various malignancies.
MGNX Stock 12 Month Forecast
Average Price Target
$3.00
▲(114.29% Upside)
Technical Analysis
Ownership Overview
11.38% Insiders
12.55% Mutual Funds
27.50% Other Institutional Investors
43.13% Public Companies and
Individual Investors